Comprehensive Dermatologic Drug Therapy
1. Part I. Introduction - p. xiv 2. 1. Basic Principles of Pharmacology - p. 1 3. 2. Principles for Maximizing the Safety of Dermatologic Drug Therapy - p. 12 4. 3. Polymorphisms: Why Individual Drug Responses Vary - p. 21 5. 4. Adherence to Drug Therapy - p. 34 6. 5. Medical Decision Making - p. 40 7. Part II. Important Drug Regulatory Issues - p. 48.e1 8. 6. The FDA Drug Approval Process - p. 49 9. 7. Pharmacovigilance: Verifying that Drugs Remain Safe - p. 54 10. 8. Drugs Taken Off the Market: Important Lessons Learned - p. 62 11. Part III. Systemic Drugs for Infectious Diseases - p. 67 12. 9. Systemic Antibacterial Agents - p. 69 13. Introduction - p. 70 14. Penicillins - p. 70 15. Cephalosporins - p. 75 16. β-Lactam and β-Lactamase Inhibitor Combinations - p. 77 17. Other Systemic Antibacterials that Inhibit Cell Wall Synthesis - p. 77 18. Macrolides - p. 78 19. Fluoroquinolones - p. 81 20. Tetracyclines - p. 82 21. Rifampin and Other Rifamycins - p. 89 22. Folate Synthesis Inhibitors - p. 93 23. Lincosamides - p. 95 24. Oxazolidinones - p. 96 25. Special Topics - p. 96 26. 10. Systemic Antifungal Agents - p. 99 27. 11. Systemic Antiviral Agents - p. 114 28. 12. Systemic Antiparasitic Agents - p. 126 29. Part IV. Systemic Immunomodulatory Drugs - p. 132.e2 30. 13. Systemic Corticosteroids - p. 133 31. 14. Methotrexate - p. 156 32. 15. Azathioprine - p. 169 33. 16. Mycophenolates - p. 178 34. 17. Cyclosporine - p. 187 35. 18. Phosphodiesterase-4 and Janus Kinase Inhibitors - p. 199 36. 19. Cytotoxic Agents - p. 209 37. 20. Dapsone - p. 222 38. 21. Antimalarial Agents - p. 234 39. 22. Systemic Retinoids - p. 245 40. Part V. Drugs Used in Conjunction with UV or Visible Light - p. 262.e4 41. 23. Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities - p. 263 42. 24. Extracorporeal Photochemotherapy (Photopheresis) - p. 271 43. 25. Photodynamic Therapy - p. 280 44. Part VI. Biologic Therapeutics - p. 286.e2 45. 26. Tumor Necrosis Factor Inhibitors - p. 287 46. 27. Interleukin 12/23 Inhibitors - p. 302 47. 28. Interleukin 17 Inhibitors - p. 312 48. 29. Interleukin 23 Inhibitors - p. 321 49. 30. Rituximab - p. 330 50. 31. Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others - p. 339 51. Part VII. Miscellaneous Systemic Drugs - p. 348.e4 52. 32. Antihistamines - p. 349 53. 33. Vasoactive and Antiplatelet Agents - p. 358 54. 34. Antiandrogens and Androgen Inhibitors - p. 366 55. 35. Psychotropic Agents - p. 382 56. 36. Intravenous Immunoglobulin Therapy - p. 397 57. 37. Systemic Anticancer Agents: Dermatologic Indications and Adverse Events - p. 405 58. 38. Hedgehog Pathway Inhibitors - p. 419 59. 39. Drugs for the Skinternist - p. 430 60. 40. Miscellaneous Systemic Drugs - p. 445 61. Part VIII. Topical Drugs for Infectious Diseases - p. 464.e6 62. 41. Topical Antibacterial Agents - p. 465 63. 42. Topical Antifungal Agents - p. 480 64. 43. Topical and Intralesional Antiviral Agents - p. 493 65. 44. Topical Antiparasitic Agents - p. 504 66. Part IX. Topical Immunomodulatory Drugs - p. 509 67. 45. Topical Corticosteroids - p. 511 68. 46. Topical Retinoids - p. 528 69. 47. Topical and Intralesional Chemotherapeutic Agents - p. 541 70. 48. Topical Calcineurin Inhibitors - p. 549 71. 49. Topical Vitamin D3 - p. 557 72. Part X. Miscellaneous Topical Drugs - p. 564.e2 73. 50. Sunscreens - p. 565 74. 51. Therapeutic Shampoos - p. 576 75. 52. α-Hydroxy Acids - p. 585 76. 53. Chemical Peels - p. 592 77. 54. Products for the Care of Chronic Wounds - p. 597 78. 55. Agents Used for Treatment of Hyperkeratosis - p. 607 79. 56. Irritants and Allergens: When to Suspect Topical Therapeutic Agents - p. 617 80. 57. Miscellaneous Topical Agents - p. 624 81. Part XI. Injectable and Mucosal Routes of Drug Administration - p. 630.e3 82. 58. Local Anesthetics - p. 631 83. 59. Injectable Dermal and Subcutaneous Fillers - p. 650 84. 60. Botulinum Toxin Injections - p. 656 85. 61. Oral Mucosal Therapeutics - p. 665 86. Part XII. Major Adverse Effects From Systemic Drugs - p. 676.e2 87. 62. Hepatotoxicity of Dermatologic Drug Therapy - p. 677 88. 63. Hematologic Toxicity of Drug Therapy - p. 689 89. 64. Drug-Induced Malignancy - p. 700 90. 65. Dermatologic Drugs During Pregnancy and Lactation - p. 710 91. 66. Drug Interactions - p. 725 92. 67. Cutaneous Drug Reactions With Systemic Features - p. 743 93. Part XIII. Special Pharmacology and Therapeutics Topics - p. 752.e4 94. 68. Informed Consent and Risk Management - p. 753 95. 69. Compounding in Dermatology - p. 759 96. 70. Dermatologic Drug Therapy in Children - p. 767 97. Appendix I. Core Questions for Understanding Systemic Dermatologic Drugs - p. 777 98. Appendix II. The Most Potentially Serious Drug Interactions - p. 784 99. Index - p. 787
Comprehensive Dermatologic Drug Therapy
1. Part I. Introduction - p. xiv 2. 1. Basic Principles of Pharmacology - p. 1 3. 2. Principles for Maximizing the Safety of Dermatologic Drug Therapy - p. 12 4. 3. Polymorphisms: Why Individual Drug Responses Vary - p. 21 5. 4. Adherence to Drug Therapy - p. 34 6. 5. Medical Decision Making - p. 40 7. Part II. Important Drug Regulatory Issues - p. 48.e1 8. 6. The FDA Drug Approval Process - p. 49 9. 7. Pharmacovigilance: Verifying that Drugs Remain Safe - p. 54 10. 8. Drugs Taken Off the Market: Important Lessons Learned - p. 62 11. Part III. Systemic Drugs for Infectious Diseases - p. 67 12. 9. Systemic Antibacterial Agents - p. 69 13. Introduction - p. 70 14. Penicillins - p. 70 15. Cephalosporins - p. 75 16. β-Lactam and β-Lactamase Inhibitor Combinations - p. 77 17. Other Systemic Antibacterials that Inhibit Cell Wall Synthesis - p. 77 18. Macrolides - p. 78 19. Fluoroquinolones - p. 81 20. Tetracyclines - p. 82 21. Rifampin and Other Rifamycins - p. 89 22. Folate Synthesis Inhibitors - p. 93 23. Lincosamides - p. 95 24. Oxazolidinones - p. 96 25. Special Topics - p. 96 26. 10. Systemic Antifungal Agents - p. 99 27. 11. Systemic Antiviral Agents - p. 114 28. 12. Systemic Antiparasitic Agents - p. 126 29. Part IV. Systemic Immunomodulatory Drugs - p. 132.e2 30. 13. Systemic Corticosteroids - p. 133 31. 14. Methotrexate - p. 156 32. 15. Azathioprine - p. 169 33. 16. Mycophenolates - p. 178 34. 17. Cyclosporine - p. 187 35. 18. Phosphodiesterase-4 and Janus Kinase Inhibitors - p. 199 36. 19. Cytotoxic Agents - p. 209 37. 20. Dapsone - p. 222 38. 21. Antimalarial Agents - p. 234 39. 22. Systemic Retinoids - p. 245 40. Part V. Drugs Used in Conjunction with UV or Visible Light - p. 262.e4 41. 23. Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities - p. 263 42. 24. Extracorporeal Photochemotherapy (Photopheresis) - p. 271 43. 25. Photodynamic Therapy - p. 280 44. Part VI. Biologic Therapeutics - p. 286.e2 45. 26. Tumor Necrosis Factor Inhibitors - p. 287 46. 27. Interleukin 12/23 Inhibitors - p. 302 47. 28. Interleukin 17 Inhibitors - p. 312 48. 29. Interleukin 23 Inhibitors - p. 321 49. 30. Rituximab - p. 330 50. 31. Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others - p. 339 51. Part VII. Miscellaneous Systemic Drugs - p. 348.e4 52. 32. Antihistamines - p. 349 53. 33. Vasoactive and Antiplatelet Agents - p. 358 54. 34. Antiandrogens and Androgen Inhibitors - p. 366 55. 35. Psychotropic Agents - p. 382 56. 36. Intravenous Immunoglobulin Therapy - p. 397 57. 37. Systemic Anticancer Agents: Dermatologic Indications and Adverse Events - p. 405 58. 38. Hedgehog Pathway Inhibitors - p. 419 59. 39. Drugs for the Skinternist - p. 430 60. 40. Miscellaneous Systemic Drugs - p. 445 61. Part VIII. Topical Drugs for Infectious Diseases - p. 464.e6 62. 41. Topical Antibacterial Agents - p. 465 63. 42. Topical Antifungal Agents - p. 480 64. 43. Topical and Intralesional Antiviral Agents - p. 493 65. 44. Topical Antiparasitic Agents - p. 504 66. Part IX. Topical Immunomodulatory Drugs - p. 509 67. 45. Topical Corticosteroids - p. 511 68. 46. Topical Retinoids - p. 528 69. 47. Topical and Intralesional Chemotherapeutic Agents - p. 541 70. 48. Topical Calcineurin Inhibitors - p. 549 71. 49. Topical Vitamin D3 - p. 557 72. Part X. Miscellaneous Topical Drugs - p. 564.e2 73. 50. Sunscreens - p. 565 74. 51. Therapeutic Shampoos - p. 576 75. 52. α-Hydroxy Acids - p. 585 76. 53. Chemical Peels - p. 592 77. 54. Products for the Care of Chronic Wounds - p. 597 78. 55. Agents Used for Treatment of Hyperkeratosis - p. 607 79. 56. Irritants and Allergens: When to Suspect Topical Therapeutic Agents - p. 617 80. 57. Miscellaneous Topical Agents - p. 624 81. Part XI. Injectable and Mucosal Routes of Drug Administration - p. 630.e3 82. 58. Local Anesthetics - p. 631 83. 59. Injectable Dermal and Subcutaneous Fillers - p. 650 84. 60. Botulinum Toxin Injections - p. 656 85. 61. Oral Mucosal Therapeutics - p. 665 86. Part XII. Major Adverse Effects From Systemic Drugs - p. 676.e2 87. 62. Hepatotoxicity of Dermatologic Drug Therapy - p. 677 88. 63. Hematologic Toxicity of Drug Therapy - p. 689 89. 64. Drug-Induced Malignancy - p. 700 90. 65. Dermatologic Drugs During Pregnancy and Lactation - p. 710 91. 66. Drug Interactions - p. 725 92. 67. Cutaneous Drug Reactions With Systemic Features - p. 743 93. Part XIII. Special Pharmacology and Therapeutics Topics - p. 752.e4 94. 68. Informed Consent and Risk Management - p. 753 95. 69. Compounding in Dermatology - p. 759 96. 70. Dermatologic Drug Therapy in Children - p. 767 97. Appendix I. Core Questions for Understanding Systemic Dermatologic Drugs - p. 777 98. Appendix II. The Most Potentially Serious Drug Interactions - p. 784 99. Index - p. 787
